ClinicalTrials.gg
CompletedNCT03782532Updated Dec 28, 2022

Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

A Phase 3 interventional study of Dupilumab SAR231893 and Placebo in Asthma, sponsored by Sanofi. Completed at 67 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
5th of 31
486 · median 120
Started
2019
with 1 other
Phase 3
11 of 31
2 open now
Registered
12th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 12th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab in patients with persistent asthma

Secondary Objectives:

  • To evaluate the safety and tolerability of dupilumab
  • To evaluate the effect of dupilumab on improving patient reported outcomes including health related quality of life
  • To evaluate dupilumab systemic exposure and immunogenicity
Read the detailed description

The total duration of study per patient is approximately 40 weeks, including 3 to 5 weeks of screening period, 24 weeks of treatment period and 12 weeks of post-treatment period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults and adolescent patients (≥12 years of age) with a physician diagnosis of asthma for ≥12 months, based on the Global Initiative for Asthma 2017 Guidelines and the following criteria:
  • Patients requiring a third controller for their asthma will be considered eligible for this study, and it should also be used for at least 3 months with a stable dose ≥1 month prior to the screening visit (Visit 1).
  • Patients requiring maintenance oral (OCS) with a stable dose ≤10 mg/day prednisone or equivalent will be allowed; OCS should be used for at least 3 months with a stable dose ≥1 month prior to the screening visit (Visit 1).
  • Pre-bronchodilator ≤ 80% of predicted normal for adults and ≤90% of predicted normal for adolescents at the screening visit and the randomization visit (Visits 1 and 2), prior to randomization.
  • Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at the screening visit and the randomization visit (Visits 1 and 2), prior to randomization.
  • For patients not requiring maintenance OCS, screening blood eosinophil count ≥150 cells/μL or Fractional Exhaled Nitric Oxide (FENO) ≥25 parts per billion (ppb); for patients requiring maintenance OCS, there is no minimum requirement for blood eosinophil count and FENO level.

Exclusion criteria

Exclusion criteria:

  • Patients \<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (for those countries where local regulations permit enrollment of adults only, patient recruitment will be restricted to those who are ≥18 years of age).
  • Weight is less than 30 kg at the screening visit (Visit 1) or the randomization visit (Visit 2).
  • or other lung diseases (eg, idiopathic pulmonary fibrosis) which may impair lung function.
  • A patient who experiences a severe asthma exacerbation (defined as deterioration of asthma that results in emergency treatment, hospitalization due to asthma, treatment with systemic , or treatment with systemic steroid at least twice the previous dose for patients on OCS maintenance) at any time from 1 month prior to the screening visit (Visit 1) up to and including the randomization visit (Visit 2).
  • Evidence of lung disease(s) other than asthma, either clinical or imaging evidence (eg, chest X-ray, computed tomography, and magnetic resonance imaging) within 3 months prior to the screening visit (Visit 1) as per local standard of care.
  • Current smoker or cessation of smoking within 6 months prior to the screening visit (Visit 1).
  • Previous smoker with a smoking history >10 pack-years.
  • Comorbid disease that might interfere with the evaluation of medicinal product (IMP).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
486 participants (actual)

Study arms

  • Experimental
    Dupilumab

    For patients without oral corticosteroids (OCS) maintenance therapy, dose 1 of dupilumab administered once in 2 weeks (q2w) with loading dose of dupilumab, two times dose 1; for patients on OCS maintenance therapy, the dose will be dupilumab dose 2 q2w with loading dose 2 times dose 2

    Drug: Dupilumab SAR231893 · Drug: Asthma Controller Therapies (include prednisone/prednisolone) · Drug: Asthma Reliever Therapies

  • Placebo comparator
    Placebo for dupilumab

    For patients without OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 1 q2w with loading dose; for patients on OCS maintenance therapy, the patients will take placebo matching to dupilumab dose 2 q2w with loading dose

    Drug: Placebo · Drug: Asthma Controller Therapies (include prednisone/prednisolone) · Drug: Asthma Reliever Therapies

Interventions

  • Pharmaceutical form: Solution Route of administration: Subcutaneous

  • DrugPlacebo

    Pharmaceutical form: Solution Route of administration: Subcutaneous

  • DrugAsthma Controller Therapies (include prednisone/prednisolone)

    Pharmaceutical form: Aerosol, capsules, tablets, oral solution Route of administration: Inhalation, oral

  • DrugAsthma Reliever Therapies

    Pharmaceutical form: Nebulized, aerosol Route of administration: Inhaled

06

What researchers measure

Primary outcomes

  1. Change in pre-bronchodilator forced expiratory volume (FEV1)

    Absolute change from baseline in pre-bronchodilator FEV1 at Week 12

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Annualized rate of severe exacerbation events

    Annualized rate of severe exacerbation events during the 24-week placebo-controlled treatment period

    Time frame: During the 24-week placebo-controlled treatment period

  2. Percent change from baseline in pre-bronchodilator FEV1

    Percent change from baseline in pre-bronchodilator FEV1 at Week 12

    Time frame: Baseline to Week 12

  3. Annualized rate of loss of asthma control (LOAC) event

    Annualized rate of LOAC event during the 24-week placebo-controlled treatment period

    Time frame: During the 24-week placebo-controlled treatment period

  4. Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit

    Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit during the 24-week placebo-controlled treatment period

    Time frame: During the 24-week placebo-controlled treatment period

  5. Time to first severe exacerbation event

    Time to first severe exacerbation event during the 24-week placebo-controlled treatment period

    Time frame: During the 24-week placebo-controlled treatment period

  6. Time to first LOAC

    Time to first LOAC during the 24-week placebo-controlled treatment period

    Time frame: During the 24-week placebo-controlled treatment period

  7. Change from baseline in Asthma Control Questionnaire (ACQ)-5 score

    Change from baseline in ACQ-5 score at Week 24

    Time frame: Baseline to Week 24

  8. Change from baseline in ACQ-7 score

    Change from baseline in ACQ-7 score at Week 24

    Time frame: Baseline to Week 24

  9. Morning/evening asthma symptom score (e-diary)

    Change from baseline at Week 24 in morning/evening asthma symptom score (e-diary)

    Time frame: Baseline to Week 24

  10. Nocturnal awakenings (e-diary)

    Change from baseline at Week 24 in nocturnal awakenings (e-diary)

    Time frame: Baseline to week 24

  11. Use of daily puffs of rescue medication

    Change from baseline at Week 24 in use of daily puffs of rescue medication

    Time frame: Baseline to Week 24

  12. Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) with Standardized Activities (≥12 years) (AQLQ+12)

    Change from baseline in AQLQ with Standardized Activities (≥12 years) (AQLQ+12) at Week 24

    Time frame: Baseline to Week 24

  13. Change from baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L)

    Change from baseline in EQ-5D-5L at Week 24

    Time frame: Baseline to Week 24

  14. Assessment of adverse events (AEs)

    Number of participants with adverse events (AEs)

    Time frame: Baseline to week 36

07

Study locations

67 sites
  • Investigational Site Number :1560013
    Baotou, 014010, China
  • Investigational Site Number :1560016
    Beijing, 100020, China
  • Investigational Site Number :1560029
    Beijing, 100029, China
  • Investigational Site Number :1560015
    Beijing, 100034, China
  • Investigational Site Number :1560056
    Beijing, China
  • Investigational Site Number :1560057
    Changchun, 130041, China
  • Investigational Site Number :1560010
    Changsha, 410013, China
  • Investigational Site Number :1560030
    Chengdu, 610041, China
  • Investigational Site Number :1560053
    Chengdu, China
  • Investigational Site Number :1560025
    Chongqing, 400038, China
  • Investigational Site Number :1560004
    Guangzhou, 510080, China
  • Investigational Site Number :1560001
    Guangzhou, 510120, China
  • Investigational Site Number :1560045
    Guangzhou, 510150, China
  • Investigational Site Number :1560032
    Guiyang, 550002, China
  • Investigational Site Number :1560019
    Hangzhou, 310003, China
  • Investigational Site Number :1560007
    Hangzhou, 310006, China
  • Investigational Site Number :1560014
    Hangzhou, 310009, China
  • Investigational Site Number :1560026
    Hangzhou, 310016, China
  • Investigational Site Number :1560043
    Hangzhou, China
  • Investigational Site Number :1560038
    Hefei, China
  • Investigational Site Number :1560044
    Hohhot, 010017, China
  • Investigational Site Number :1560008
    Hohhot, 010050, China
  • Investigational Site Number :1560022
    Lanzhou, 730000, China
  • Investigational Site Number :1560024
    Nanchang, 330006, China
  • Investigational Site Number :1560051
    Nanjing, 210005, China
  • Investigational Site Number :1560054
    Nanjing, 210006, China
  • Investigational Site Number :1560037
    Nanjing, 210029, China
  • Investigational Site Number :1560035
    Pingxiang, 337055, China
  • Investigational Site Number :1560050
    Shanghai, 200025, China
  • Investigational Site Number :1560049
    Shanghai, 200030, China
  • Investigational Site Number :1560005
    Shanghai, 200032, China
  • Investigational Site Number :1560011
    Shanghai, 200080, China
  • Investigational Site Number :1560017
    Shanghai, 200120, China
  • Investigational Site Number :1560006
    Shanghai, 200233, China
  • Investigational Site Number :1560002
    Shanghai, 200433, China
  • Investigational Site Number :1560018
    Shenyang, 110001, China
  • Investigational Site Number :1560036
    Shenyang, 110004, China
  • Investigational Site Number :1560012
    Shenzhen, 518020, China
  • Investigational Site Number :1560042
    Shenzhen, 518102, China
  • Investigational Site Number :1560003
    Shijiazhuang, 050000, China
  • Investigational Site Number :1560041
    Shijiazhuang, 050041, China
  • Investigational Site Number :1560031
    Suzhou, 215006, China
  • Investigational Site Number :1560048
    Taiyuan, 030001, China
  • Investigational Site Number :1560020
    Tianjin, 300052, China
  • Investigational Site Number :1560033
    Urumchi, 830054, China
  • Investigational Site Number :1560021
    Wenzhou, 325000, China
  • Investigational Site Number :1560052
    Wuhan, 430000, China
  • Investigational Site Number :1560028
    Wuhan, 430030, China
  • Investigational Site Number :1560040
    Xi'an, China
  • Investigational Site Number :1560046
    Xiamen, 361004, China
  • Investigational Site Number :1560027
    Xiangtan, China
  • Investigational Site Number :1560023
    Xuzhou, 221002, China
  • Investigational Site Number :1560055
    Yangzhou, 225001, China
  • Investigational Site Number :1560047
    Zhanjiang, 524001, China
  • Investigational Site Number :3560006
    Chandigarh, 160012, India
  • Investigational Site Number :3560002
    Coimbatore, 641028, India
  • Investigational Site Number :3560013
    Hyderabad, 500082, India
  • Investigational Site Number :3560005
    Jaipur, 302023, India
  • Investigational Site Number :3560015
    Jaipur, 302039, India
  • Investigational Site Number :3560010
    Kolkata, 700107, India
  • Investigational Site Number :3560011
    Kozhikode, 673008, India
  • Investigational Site Number :3560012
    Mohali, 160062, India
  • Investigational Site Number :3560003
    Nagpur, 440012, India
  • Investigational Site Number :3560016
    Nagpur, 440012, India
  • Investigational Site Number :3560001
    New Delhi, 110060, India
  • Investigational Site Number :3560009
    Pune, 411001, India
  • Investigational Site Number :3560007
    Vellore, 632004, India
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in May 2022, 39 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 39 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 20, 2018
StartActual
Jan 25, 2019
Primary completionActual
May 21, 2022
CompletionActual
May 21, 2022
Last update
Dec 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03782532
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 20, 2018
Start date
Jan 25, 2019
Primary completion
May 21, 2022
Completion
May 21, 2022
Last update
Dec 28, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion